Homologous Recombination News and Research

RSS

MGI and OncoDNA join forces to offer laboratories a streamlined NGS workflow for implementing Comprehensive Genomic Profiling (CGP) OncoDEEP® Kit in clinical practice

MGI (MGI Tech Co., Ltd. or its subsidiaries, together referred to MGI), a company committed to building core tools and technologies that drive innovation in life science, today announced the collaboration with OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases.

From MGI 29 Oct 2024

New gene variants linked to early menopause and cancer risk identified

Study reveals nine gene variants linked to ovarian aging and cancer risk, with implications for reproductive longevity and de novo mutation rates.

12 Sep 2024

Study reveals RAD51D variant enrichment in Chinese ovarian cancer patients

Researchers from BGI Genomics and Fudan University published new findings on OV among Chinese patients in JCO Global Oncology.

22 Aug 2024

UC San Diego develops AI tool for rapid, low-cost detection of genomic alterations in cancer

A new generation of artificial intelligence (AI) tools designed to allow rapid, low-cost detection of clinically actionable genomic alterations directly from tumor biopsy slides has been developed by a team led by engineers and medical researchers at University of California San Diego.

1 Aug 2024

Insilico Medicine's AI-designed drug ISM3412 receives FDA IND approval

Clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine announces that it has received approval from the U.S. Food and Drug Administration for its Investigational New Drug application for ISM3412, a small molecule inhibitor of MAT2A for the potential treatment of MTAP deleted cancers designed with Insilico's generative AI platform.

25 Apr 2024

Protecting telomeres: ILF3 and the regulation of R-loop dynamics

Dysregulated R-loops can cause stalled replication forks and telomere instability. However, how R-loops are recognized and regulated, is still not well understood, particularly at telomeres.

22 Apr 2024

Study identifies CDK9's involvement in DNA repair during cell division

Researchers describe a newly-observed role for the protein Cyclin Dependent Kinase 9 (CDK9) in regulating DNA repair during cellular division, where errors can become the origin of cancerous tumor growth.

14 Mar 2024

Combo of targeted and immunotherapy may boost NSCLC treatment by overcoming immune resistance and enhancing anti-tumor activity

Researchers evaluated rational combination treatment regimens for advanced/metastatic non-small-cell lung cancer (NSCLC).

15 Feb 2024

Combination therapy offers breakthrough in NSCLC treatment

A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.

13 Feb 2024

RecA protein skips "unwinding" step in DNA repair

Researchers from Tokyo Metropolitan University have been studying DNA repair by homologous recombination, where the RecA protein repairs breaks in double-stranded DNA by incorporating a dangling single-strand end into intact double strands, and repairing the break based on the undamaged sequence.

20 Jan 2024

Combining health data with whole genome sequence data in cancer patients can help doctors provide more tailored care

Researchers evaluated the impact of integrating whole-genome sequencing data with clinical outcomes across 13,880 tumors from 33 cancer types, assessing precision care potentials within the UK NHS through the 100,000 Genomes Cancer Programme.

16 Jan 2024

Study uncovers new weapon against PARP inhibitor-resistant ovarian cancers

A new editorial paper was published in Oncotarget's Volume 14 on December 22, 2023, entitled, "One more step toward treatment of PARP inhibitor-resistant ovarian cancers."

10 Jan 2024

Science, Innovation, and Xenotransplantation: A Discussion with Dr. Wenning Qin

In this interview, we delve deep into the pioneering world of xenotransplantation and the evolving landscape of gene editing.

2 Nov 2023

Newly identified small molecule can suppress growth of breast and ovarian cancers in animal models

Researchers at Baylor College of Medicine have identified a small molecule named 5D4 that can suppress the growth of breast and ovarian cancers in animal models.

25 Oct 2023

How chromatin compartmentalization affects DNA damage response

Researchers uncover novel insights into how chromatin compartmentalization influences the DNA damage response (DDR) after double-stranded breaks (DSBs), shedding light on the mechanisms behind genomic integrity maintenance and the risk of translocations. Their findings reveal the importance of chromosomal design in DNA repair and the potential implications for genome stability and cancer translocations.

22 Oct 2023

Recent Advancements in Cell Based Therapy

In this interview, NewsMedical talks to James Brady about cell-based therapy and how the field of genetic engineering transformed.

From MaxCyte, Inc. 11 Oct 2023

NICER: A safer alternative to CRISPR/Cas9 for gene editing

The gene editing technique CRISPR/Cas9 has allowed researchers to make precise and impactful changes to an organism's DNA to fix mutations that cause genetic disease.

15 Sep 2023

Long DNA molecules reveal new scar types in HR-deficient cancers

DNA can be damaged by toxins, radiation, or even normal cell division, but human cells must continually fix DNA breaks to survive.

16 Aug 2023

Study provides new insights into the mechanism of Dmc1 filament assembly

Homologous recombination (HR) is an important process that plays multiple crucial roles during meiosis, a type of cell cycle dedicated to sexual reproduction.

19 Jul 2023

Analyzing the role of LP-284 Hodgkin's lymphoma models and in DNA damage repair

A new research paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, "LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair."

13 Jun 2023